Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
1. Glioblastoma: Overview of biological hallmarks and molecular pathology
2. Contemporary drug treatment of glioblastoma
3. Investigational new drugs against glioblastoma
4. The hallmarks of anti-cancer drug resistance: An overview
5. Molecular mechanisms of innate and acquired temozolomide resistance in glioblastoma
6. Glioma stem cells and associated molecular mechanisms in glioblastoma chemoresistance
7. Molecular and cellular mechanisms in recurrent glioblastoma chemoresistance
8. Intratumoral heterogeneity associated with glioblastoma drug response and resistance
9. The molecular and cellular effects of radiotherapy-induced microenvironment changes on potential chemoresistance in glioblastoma
10. Role of apoptosis, autophagy and the unfolded protein response in glioblastoma chemoresistance
11. Drug penetration through the BBB after radiotherapy: new approaches to bypass glioblastoma chemoresistance
12. Role of multi-drug resistance (ABC and solute carrier transporters) in glioblastoma chemoresistance
13. Glioblastoma cell-induced immunosuppression causing chemoresistance
14. Impediments to drug delivery in glioblastoma treatment: Nove delivery strategies past the BBB
15. 3D in vitro models to study potentiation of gliobastoma resistance by hypoxia
16. On-chip analysis of glioblastoma chemoresistance
17. Chemoresistance mechanisms in mouse models of glioblastoma
18. Mechanism of glioblastoma chemoresistance to bevacizumab
19. Treatment and resistance of glioblastoma to CAR-T cell immunotherapies
20. Therapeutic approaches to overcome temozolomide resistant glioblastoma
21. Metabolic strategies to overcome glioblastoma chemoresistance
22. Understanding signal transduction pathways to overcome targeted therapy resistance in glioblastoma
23. Therapies to target the molecular mechanisms of glioma stem cell resistance to chemotherapy
24. Vaccines to limit resistance against glioblastoma therapy
25. Role of BMP and TGF-β signaling in glioblastoma drug resistance and strategies for therapeutic intervention
26. Role of cell quiescence in glioblastoma drug resistance and strategies for therapeutic intervention
27. Role of IncRNAs in temozolomide-resistant glioblastoma
28. Role of mitochondiral reactive oxygen species release in glioblastoma drug resistance and strategies of therapeutic intervention
29. Role of miRNA therapy in pre-sensitizing glioblastoma cells to temozolomide treatment
30. Small molecules targeting p53 stabilization as a therapeutic strategy
31. Small molecules targeting misfolded mutants of p53 as a rescue strategy to improve chemotherapy
32. p53 supplementation as a targeted cancer gene therapy for glioblastoma
Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists, neuro-oncologists and other members of the biomedical field.
Glioblastoma (GBM) is the most invasive and malignant primary brain tumor in humans with poor survival after diagnosis, therefore it is imperative that molecular and cellular mechanisms behind therapy resistant GBM cells, as well as the therapeutic strategies available to counter the resistance are comprehensively understood.
- Provides comprehensive, core knowledge related to the entire discipline of glioblastoma chemoresistance, from its many etiological mechanisms, to specific strategies to reverse resistance
- Presents current information from an international team of experts on the basic science, pre-clinical research, and clinical management of glioblastoma chemoresistance
- Discusses molecular and cellular mechanisms behind therapy resistant glioblastoma cells, as well as the therapeutic strategies available to counter this resistance
Cancer researchers, medical scientists, clinicians, graduate students. Neuro-oncologists
- No. of pages:
- © Academic Press 2021
- 1st May 2021
- Academic Press
- Hardcover ISBN:
Dr. Massoud has expertise in molecular imaging, translational cancer imaging, neuro-oncology, and applications and perspectives relevant to clinical cancer management of glioblastoma patients.
Professor, Molecular Imaging Program at Stanford, and Department of Radiology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA
Dr. Paulmurugan has expertise in molecular imaging, pre-clinical cancer imaging, cancer biology, nanotechnology, and molecular biotechnology.
Associate Professor, Molecular Imaging Program at Stanford, and Department of Radiology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.